Trial Search Results

Stereotactic Radiation Therapy for Pediatric Sarcomas

The SBRT (stereotactic body radiation therapy) literature focuses on clinical outcomes in the adult population. However, SBRT (stereotactic body radiation therapy) has a particularly strong rationale for application in pediatrics given that high biologically effective doses have been shown to increase control in histologies, such as sarcoma, which are common in the pediatrics population (11,25). With stereotactic radiation therapy techniques, a reduction in normal tissue dose surrounding the target lesion of interest may also be accomplished resulting in lower toxicity. Given that pediatric patients with sarcomas, presenting with limited metastases in lung and bone, are still considered to be a curable population with aggressive local therapy, SBRT could have a significant impact on outcomes in oligometastatic patients who may be otherwise unresectable (25-28).

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Sidney Kimmel Comprehensive Cancer Center

Stanford Investigator(s):


  • Radiation: SBRT


Phase 2


Inclusion Criteria:

   - confirmed sarcoma of the soft tissue or bone

   - must have measurable disease via CT scan

   - tumor malignancies must meet certain criteria to be eligible

   - greater than 3 years of age

   - less than or equal to 40 years of age

   - life expectancy of at least 9 months

   - adequate performance status

   - ability to understand and willingness to sign informed consent document

Exclusion Criteria:

   - patients who have had chemotherapy or radiotherapy within 2 weeks prior to entering
   the study

   - patients who have had any prior radiotherapy to the treatment site(s)

   - patients may not participate on any other treatment protocol while they are receiving
   treatment on this protocol and for up to 3 months after these protocol treatments have

   - pregnant women

   - refusal of women of child bearing potential to take a pregnancy test prior to

Ages Eligible for Study

4 Years - 40 Years

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Iris Gibbs, MD